SAHAR EFTEKHAR: Open Payments
NPI 1376819565 · CHICAGO, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,946 in 99 payments from 16 companies in 2025. Trend: 2023 $1,896 · 2024 $1,837 · 2025 $1,946
Food & beverage: $1,946
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 18 | $578 |
| ABBVIE INC. | 24 | $363 |
| Janssen Pharmaceuticals, Inc | 5 | $167 |
| Lundbeck LLC | 21 | $163 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $154 |
| Bausch Health US, LLC | 6 | $119 |
| E.R. Squibb & Sons, L.L.C. | 4 | $88 |
| Axsome Therapeutics, Inc. | 3 | $56 |
| Supernus Pharmaceuticals, Inc. | 1 | $47 |
| Biogen, Inc. | 2 | $47 |
Products named: REXULTI, VRAYLAR, SPRAVATO, CAPLYTA, APLENZIN, Auvelity, COBENFY, Qelbree.
Industry payments across IL — which companies pay providers there.
